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Abstract
Introduction: We used DR1 transgenic mice and covalently linked DR1 multimers to characterize analog-specific
inhibitory T cells in collagen-induced arthritis (CIA). Because of the low numbers of antigen-specific T cells in wild-
type mice, functional T-cell studies in autoimmune arthritis have been challenging. The use of T-cell receptor (TCR)
transgenic mice has provided useful information, but such T cells may not represent the heterogeneous T-cell
response that occurs in natural settings. Our focus was to develop tools to identify and characterize the population
of immunoregulatory T cells induced in wild-type mice by an analog peptide of CII259-273, which contains amino
acid substitutions at positions 263 (N) and 266 (D) (analog peptide A12).
Methods: DR1 multimers, developed by loading empty class II molecules with exogenous peptide, provide a
method for visualizing antigen-specific T cells with flow cytometry. However, the low binding avidity of A12 for the
major histocompatibility complex (MHC) made this strategy untenable. To overcome this problem, we generated
DR1 multimers in which the analog peptide A12 was covalently linked, hoping that the low-avidity analog would
occupy enough binding clefts to allow detection of the responsive T cells.
Results: Staining with the tetramer revealed that A12-specific T cells were readily detectable at 10 days after
immunization. These CD4(+) T cells are a highly selective subset of the TCR repertoire and have a limited clonality.
Analysis of cytokine expression showed that cells detected by tetramer (A12) expressed primarily suppressive
cytokines (interleukin-4 (IL-4) and IL-10) in response to collagen, compared with control cells. Although they did
not express Fox-p3, they were extremely effective in preventing and suppressing inflammatory arthritis.
Conclusions: In summary, our studies showed that the use of covalently linked multimers allows characterization
of analog-specific T cells that are otherwise difficult to detect. The suppressive character of the analog-specific T-
cell response suggests that these cells attenuate autoimmunity and differ significantly in phenotype from the
inflammatory T cells predominantly found in arthritic joints. Such reagents will become powerful tools to study T-
cell responses in RA patients in upcoming clinical trials.
Introduction
Rheumatoid arthritis (RA) is a systemic disease consisting
of chronic inflammation in multiple articular joints.
Current treatments such as systemic anti-tumor necrosis
factor (TNF)-a therapies are effective in > 50% of RA
patients [1]; however, biologics must be given in relatively
high dosages, and significant side effects have been
reported [2]. The success of the best-known altered pep-
tide ligand, Copaxone (Teva Pharmaceuticals, Petach
Tikva, Israel.) as a first-line therapy for multiple sclerosis
(MS), suggests that peptide therapies based on naturally
occurring proteins may provide an effective alternative to
drug biologics for the treatment of arthritis. Although
various strategies have been tested, we have developed a
unique modification to a protein that is the predominant
collagen type found in human cartilage. Our therapy is
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based on our previous discovery of an analog peptide of
type II collagen (CII) that could profoundly suppress
arthritis in the CIA model by inducing a unique inhibi-
tory T cell [3].
Although the original observations were made by using
DBA/1 mice, we have extended our findings to a huma-
nized animal model specifically developed to mimic more
closely the pathogenic features of RA. In this model, mice
transgenic for one of the most common RA-susceptible
major histocompatibility complex (MHC) molecules,
DRB*0101 (DR1) [4,5] become arthritic when immunized
with CII/CFA. By using proliferation and cytokine assays,
we determined that a peptide representing CII263-270 and
containing amino acid substitutions at positions 263
(F®N) and 266 (E®D) (analog peptide A12) was pro-
foundly suppressive, effectively attenuating arthritis in the
humanized RA-mouse models, despite having very poor
avidity for the MHC [6].
Although collagen peptides designed with carefully
crafted substitutions such as A12 may provide an attrac-
tive alternative choice for treatment of RA, the low num-
bers of antigen-specific T cells in wild-type mice have
made functional T-cell studies in autoimmune arthritis
particularly challenging. Studies using TCR transgenic
T cells are limited to the study of one TCR, and the low
MHC binding avidity of peptide A12 makes untenable
the strategy of loading empty class II molecules with exo-
genous peptide to be assembled as MHC multimers (tet-
ramers). To overcome this problem, we generated DR1
multimers [7,8], in which the analog peptide A12 was
covalently linked, making it more likely that majority of
the MHC molecule binding clefts are occupied by this
peptide [9-11]. By using the tetramers as a tool to study
analog-responsive T cells, we immunized DR1 tg mice
with A12/CFA and isolated draining inguinal lymph node
cells. Culture with the tetramer revealed that A12-speci-
fic T cells were readily detectable. Moreover, the A12-
responsive T cells could be visualized to characterize the
TCR-Vb repertoire and cytokine secretion profiles.
Adoptive transfer experiments demonstrated that tetra-
mer+ cells were very effective in preventing and suppres-
sing inflammatory arthritis.
Looking to the future, class II tetramers, such as DR1-
A12 show promise for monitoring the development of
analog-specific T cells in clinical settings whenever low-
avidity analog peptides will be used to treat patients with
RA.
Materials and methods
Preparation of tissue-derived CII and synthetic peptides
Native CII was solubilized from fetal calf articular carti-
lage by limited pepsin-digestion and purified as described
earlier [12]. The purified collagen was dissolved in cold
20 mM acetic acid at 4 mg/ml and stored frozen at -70°C
until used. The synthetic peptides were supplied by Bio-
molecules Midwest Inc. (Waterloo, IL, USA). A peptide
containing the immunodominant determinant sequence
of CII (GIAGFKGEQGPKGEB) is referred to as A2 or
wild-type (WT) IEDBID 109115; a synthetic peptide
representing the sequence (GIAGNKGDQGPKGEB) is
designated A12.
Animals
Generation of Tg mice expressing DR
Mice expressing the chimeric (human/mouse)
DRB1*0101 construct were maintained in our onsite
pathogen-free facility. The chimeric DRB1*0101 con-
struct has been previously described, as has the produc-
tion of Tg mice expressing these constructs [4].
Generation of DR1 mice that are IL4 or IL10 knockout
The IL-4 (C57BL/6-IL4tm1cgn IL-4 and C57BL/6-IL10tm1cgn
knockout) mice were purchased from Jackson Labora-
tory (Bar Harbor, ME, USA) and backcrossed onto the
arthritis-susceptible DR1 C57BL/10 background for 12
generations before they were intercrossed. Genomic
DNA was obtained from blood samples, and polymerase
chain reaction (PCR) was used to identify mice homozy-
gous for the IL-4-/- and IL-10-/- phenotypes.
All mice were fed standard rodent chow (Ralston Purina
Co., St. Louis, MO, USA) and water ad libitum. To ensure
that the environment was pathogen free, sentinel mice
were routinely tested for hepatitis and Sendai viruses. All
animals were kept until the age of 7 to 10 weeks before
being used for experiments, which were conducted in
accordance with approved IACUC protocols.
Immunization
CII was dissolved in 10 mM acetic acid at a concentration
of 4 mg/ml and emulsified with an equal volume of CFA
containing 4 mg/ml of Mycobacterium tuberculosis strain
H37 Ra (Difco Microbiology Products, Becton Dickinson,
Franklin Lakes, NJ, USA) [12]. For the induction of arthri-
tis, each mouse received 100 μg of CII emulsified in CFA
subcutaneously at the base of the tail. For other immuni-
zations, each mouse received subcutaneously 100 μg of
either peptide A12 or Ova emulsified with CFA.
Measurement of the severity of arthritis
The severity of arthritis were determined by visually
examining each forepaw and hindpaw and scoring them
on a scale of 0 to 4, as described previously [12]. Scoring
was conducted by two examiners, one of whom was una-
ware of the identity of the treatment groups. Each mouse
was scored thrice weekly, beginning 3 weeks after immu-
nization and continuing for 8 weeks. The mean severity
score (sum of the severity scores for the group on each
day/total number of animals in the group) was recorded
at each time point.
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Production of soluble HLA-DR protein
Soluble DR1 was purified from culture supernatants of S2
Drosophila cells previously transfected with DRB1*0101
and DRA1*0101. Both the a- and b-chains of the DR1
constructs contain murine I-E leader sequences, followed
by DRa or DRb first domains and murine I-Ea and I-Eb
second domains. The analog (CII259-273, 263F, 266D),
was inserted after the third residue of the b-chain, and a
flexible ((Gly)4-Ser)3 linker was added to allow the pep-
tide to fold into the binding groove of the DR molecule.
The sequences encoding the cytoplasmic and transmem-
brane portions of the molecules were deleted from the
cDNA by PCR, and a new stop codon was inserted at the
3’ end of the second domain of the a-chain. The b-chains
were altered by adding a linker and a biotinylation site 3’
to the Eb second domain, to allow site-specific addition
of biotin and tetramerization by using streptavidin. The
resulting cDNA was cloned into the Drosophila expres-
sion vector pRmHA-3 (gift from Dr. D. Zaller, Merck,
Rahway, NJ, USA). S2 cells were transfected with a
10:10:1 ratio of chimeric DRB1 and DRA1 to pUChsNeo
by using calcium phosphate precipitation. Soluble DR
production was induced by 1 mM CuSO4, and 5 days
later, the culture supernatant was collected and adjusted
to 0.05% octyl glucoside (OcG). The DR molecules were
purified by passage of the culture supernatant over an
affinity column coupled with the anti-DR Ab LB3.1. The
column was washed with 0.05% OcG and 0.15 M NaCl in
phosphate buffer, pH 7.5, followed by 0.05% OcG and 0.5
M NaCl in phosphate buffer, pH 7.5, and a final wash
with 10 mM Tris in 0.5 M NaCl, pH 7.5. The DR mole-
cules were eluted with 100 mM Tris and 0.5 M NaCl, pH
11.2, and the fractions were immediately neutralized with
acetic acid. The DR recovered was concentrated by using
an Amicon Stirred Cell, quantitated by OD280 absorp-
tion and ELISA (PathScan Total DDR1 Sandwich ELISA
Kit; Cell Signaling, Danvers, MA, USA), and was evalu-
ated with SDS-PAGE before use. Biotinylation of the pro-
teins was performed with BirA (Avidity, Denver, CO,
USA) and incorporated into saturated complexes with
phycoerythrin (PE)-streptavidin (BioSource International,
Camarillo, CA, USA) before use.
Tetramer binding
For tetramer staining of T cells, lymph node cells were
diluted to a concentration of 2.5 × 107/ml in DMEM
medium (Gibco) supplemented with 50 U/ml penicillin
G sodium, 50 μg/ml streptomycin sulfate, 0.05 mM 2-
ME, 2 mM L-glutamine, and 0.1% BSA, and T-hybridoma
cells were diluted to a concentration of 2.5 × 106/ml in
DMEM complete. One million lymph node cells or 105
T-hybridoma cells were then aliquoted into a 96-well
plate and were incubated with 1 μg of tetramer in 10 μl
of complete medium supplemented with 5 mM NaN3.
Cells were incubated at 37°C for 2.5 hours, at which time,
antibodies to cell-surface markers were added, and cells
were incubated for an additional 30 minutes at 4°C. After
incubation with Abs to cell-surface markers, samples
were washed 3 times with 200 μl of PBS supplemented
with 0.1% NaN3 and 2% FBS, resuspended in 200 μl of
PBS supplemented with 0.1% NaN3 and 2% FBS, and ana-
lyzed with flow cytometry by using a FACSCalibur (BD
Biosciences). In some experiments, the draining lymph
nodes of DR1 mice were harvested 10 days after immuni-
zation with CII and were incubated with tetramer and
subjected to magnetic sorting to obtain a purified popula-
tion of tetramer-positive cells (Miltenyi Biotec).
Flow cytometry analysis of TCR repertoire
To determine the frequency of individual Vb subfamilies
expressed by tetramer+ T cells in DR1 mice, draining
inguinal cells from DR1 mice immunized 10 days earlier
with A12/CFA were incubated with tetramer labeled with
PE, anti-CD4-APC, anti-a/bTCR-PerCP (BD Biosciences,
San Jose, CA, USA), and an anti-TCR-Vb-specific Ab
conjugated with FITC for 30 minutes at 4°C (Mouse Vb
TCR Screening Panel; BD Biosciences). Labeled cells
were washed with PBS, and a minimum of 10,000 cells
was analyzed from each sample with flow cytometry by
using a FACSCalibur or LSR II (BD Biosciences). The
final analysis was performed by using FlowJo software
(Tree Star, Ashland, OR, USA).
Measurement of serum antibody titers
Mice were bled at 6 weeks after immunization, and sera
were analyzed for antibodies reactive with native CII by
using a modification of an enzyme-linked immunoassay
(ELISA) previously described [12]. Serial dilutions of a
standard serum were added to each plate. From these
values, a standard curve was derived by computer analy-
sis by using a four-parameter logistic curve. Results are
reported as units of activity, derived by comparison of
test sera with the curve derived from the standard serum,
which was arbitrarily defined as having 50 units of activ-
ity. Reactivity to CII was not detected in sera obtained
from normal mice.
Phenotypic characterization of the cells
Inguinal lymph nodes from immunized mice were iso-
lated, and the phenotype induced by A12 was determined
by multiparameter flow cytometry with an LSRII flow cyt-
ometer (BD Biosciences). Cells were cultured with fluoro-
chrome-labeled antibodies specific for CD4, CD25, or
CD44 (BD Biosciences) as well as tetramer. In some
experiments, intracellular labeling was performed by using
antibodies specific for FoxP3 (FJK-16s; eBioscience, San
Diego, CA, USA), per the manufacturer’s protocol. In the
experiments involving intracellular staining, specific gating
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was performed on both the CD4+ and the Vb8+, Vb14+
population of cells.
Passive-transfer experiments
In transfer experiments, inguinal lymph node cells from
DR1 mice previously immunized with the A12 analog
peptide in CFA were collected 8 days after immuniza-
tion, and various cell subsets were fractionated by using
PE-labeled tetramers and ferromagnetic beads (Miltenyi
Biotec, Gladbach, Germany), according to the manufac-
turer’s protocol. The purity of each cell population was
confirmed by flow cytometry to have > 95% purity. Reci-
pient mice were given cells intravenously by using two
protocols (a) 2 × 105 either tetramer+ or tetramer- T
cell or (b) 5 × 105 of VB8+, VB14+ T cells. All recipient
mice were immunized with CII either on the day of the
cell transfer (prevention protocol) or 25 days before cell
transfer (therapy protocol) and observed for arthritis.
Measurement of cytokines
To measure cytokines, inguinal CD4+ lymph node cells
or purified tetramer+ T cells were cultured (5 × 105
CD4+ T cells/ml) with wild-type APCs (DR1-positive
splenocytes) (1:2 ratio), which had been prepulsed with
100 μg/ml of the various peptides (A2 or A12). The
CD4+ cells were collected 8 days after immunization
(with either OVA, CII, or A12 emulsified in CFA) by
negative selection by using ferromagnetic beads, accord-
ing to the manufacturer’s protocol (Miltinyi Biotech).
(Each cell population was confirmed by flow cytometry
to have > 95% purity). Each culture was set up by using
pooled cells from three mice run in triplicates, and
supernatants were collected at 72 hours and analyzed
for the presence of IL-4, IL-10, IL-2, INF-g, and IL-17
by using a Bio-plex mouse cytokine assay (Bio-Rad, Her-
cules, CA, USA) according to the manufacturer’s proto-
col. Values are expressed as picograms per milliliter and
represent the mean values for each group taken from
three separate experiments.
Statistical analysis
Mean severity scores, antibody titers, and cytokine levels
were compared by using the Mann-Whitney test.
Results
Functional analysis of chimeric recombinant soluble DR
molecules
We previously reported that the A12-induced suppres-
sion of arthritis is achieved primarily by T cells [13]. To
identify and characterize clearly the cells responsible for
this effect, we generated DR1 multimers (tetramers) that
have a covalently linked collagen analog, so that the A12
peptide occupies the majority of the MHC molecule
binding clefts [9-11]. Biotinylated DR1-A12 molecules
were generated and assembled into tetramers by using
phycoerythrin-streptavidin. To determine the binding
specificity of our tetramer, we used a well-characterized
panel of DR1-restricted CII-specific T-cell hybridomas
[8,14] and cultured them with the A12-tetramer before
analysis with flow cytometry. As shown in Figure 1, the
A12-tetramer bound only to the collagen-specific DR1
restricted hybridomas (example, DR1-E174, middle
panel, Figure 1, which is representative of nine individual
CII-specific hybridomas (mean fluorescence (MF) =
11,400 ± 392). Conversely, the tetramer was antigen spe-
cific, unable to recognize DR1-restricted hybridomas that
are specific for hemagglutinin (example, DR1.HA.8; right
panel, Figure 1, a DR-1 restricted hybridoma that recog-
nized HA, MF = 493 ± 256; n = 4). Finally, we deter-
mined that the tetramer binding was MHC specific,
incapable of binding collagen-specific hybridomas that
were restricted by another MHC (for example, DR4-
restricted collagen-specific hybridomas, MF = 462 ± 280,
n = 4, P < 0.0001; compared with the MF of 11,400 ± 392
of the DR1-restricted CII-specific hybridomas, n = 9).
These data confirm that that our A12/DR1-tetramer
recognizes only the collagen-specific, DR1-restricted T
cells in our panel.
Identification of A12-specific T cells in vivo
Although the concept of “suppressor” T cells was first
put forward 40 years ago [15], an increasing number of
immune cell populations have been reported to play a
role in the regulation of autoimmunity [16]. Therefore,
it is important to characterize precisely the cells induced
by the analog peptide A12. We chose to search for the
A12-specific T cells directly ex vivo. DR1 mice were
immunized with A12 or Ova (as a control), and 10 days
later, T cells from inguinal lymph nodes were stained
with DR1-A12 tetramer and anti-CD3, either immedi-
ately or after 4 days of restimulation in culture with the
A12 peptide. As shown in Figure 2, an increase in the
percentage and number of CD3+ T cells that bound the
DR1-A12 tetramer could be observed both ex vivo and
after stimulation in culture compared with controls.
Although the ex vivo analyses of DR1-restricted, A12-
specific T cells revealed only a small population of tetra-
mer+/CD3+ T cells (1.5% ± 0.3% versus 0.5% ± 0.3%; P ≤
0.05; n = 6), by day 4 of stimulation in culture, a clearly
discernible population (8.5% ± 0.5% versus 0.5% ± 0.4%;
P ≤ 0.05; n = 6), representing a fivefold expansion of
cells, was visible. The specificity of the tetramer staining
was quite clear, because nonspecific binding (cells
derived from DR1 mice that had been immunized with
Ova, but stained with a DR1/A12 peptide tetramer) was
extremely low (Figure 2b, d).
In clinical settings, analog peptides will be adminis-
tered therapeutically during episodes of active arthritis.
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To characterize the A12-specific T-cell response that
develops within an inflammatory milieu, DR1 mice were
immunized with CII/CFA, and once arthritis was clearly
established, the mice were treated subcutaneously with
A12 peptide. When the DR1-A12 multimers were used
to stain inguinal lymph node cells from arthritic mice
evaluated 26 days after peptide treatment, a distinct
population of tetramer+ cells was detected in the A12-
treated mice (1.2% ± 0.5% versus 0.2% ± 0.3%; P ≤ 0.05;
n = 6; Figure 2e). Again the specificity of the tetramer
staining was clear, because nonspecific tetramer binding
by cells derived from DR1 mice that had been immu-
nized with Ova remained low (Figure 2f).
Oligoclonality and phenotype of A12-specific T cells
Although we previously reported that CII-specific T
cells restricted by DR1 are clearly oligoclonal [8], the
degree of heterogeneity among analog A12-responding
T cells remained unclear. Therefore, we analyzed the T
cells that migrated to the inguinal lymph nodes after
immunization with A12 and analyzed them for TCR b-
chain variability. As shown in Table 1, when cells were
analyzed by specifically gating on individual Vb popula-
tions after co-staining with tetramer, two Vb types were
explicitly preferred, Vb8 (Vb8.1, Vb8.2, or Vb8.3) and
Vb14. A significant tetramer+ T-cell population was
detected in each of these two subsets (Vb8 and Vb14),
whereas all other Vb antibodies tested had tetramer
levels indistinguishable from background. Collectively,
Vb14 and Vb8 accounted for > 97% of the tetramer+ T
cells, thus identifying them as the major T-cell popula-
tion responding to the A12 analog determinant pre-
sented by DR1. The tetramer-negative cells had a T-cell
repertoire comparable to that of wild-type DR1 mice,
which we previously reported [8].
Our next approach was to characterize the phenotype
of the heterogeneous CD4+ T-cell subset generated by
interaction with A12 by using multiparameter flow cyto-
metry. Naive T cells activated by antigen/APC interaction
are expected to expand and differentiate into effector
T cells, forming subpopulations that express activation
markers, such as CD25, and memory markers, such as
CD44. We previously showed that T cells recognizing the
immunodominant T-cell determinant of CII upregulate
both activation and memory markers on stimulation with
CII [7,17]. However, when A12-tetramer+ cells were
tested for the presence of activation and memory mar-
kers, their expression (CD25 and CD44) was undetect-
able either directly ex vivo or after 4 days of culture (data
not shown). Similarly, the numbers of Tregs (identified as
Foxp3+ and CD25+; Figure 3) remain at background
levels in populations of CD4+, VB8+, and VB14+ T cells
that have been immunized with A12/CFA. Taken
together, our data reveal that a population of A12-speci-
fic inhibitory T cells migrates to the inguinal lymph
nodes after immunization with A12/CFA and develops a
distinct oligoclonal TCR response without memory, acti-








Figure 1 Functional analysis and specificity of the recombinant DR1-A12. Tetrameric DR1-A12 was tested for its ability to bind specifically
to DR1-restricted, CII-specific T cells. A panel of T-cell hybridomas was cultured with the tetramers in saturating concentrations at 37°C for 3
hours. An anti-CD4 antibody was added in the last 30 minutes before the cells were washed and analyzed on the flow cytometer. The left panel
demonstrates an unstained control. The middle panel shows hybridoma DR1.E174, which is representative of tests performed on nine individual
CII-specific DR1-restricted hybridomas. The right panel (DR1.HA.8) is representative of four control T-cell hybridomas specific for an HA peptide in
the context of DR1. Previous testing has shown that none of these hybridomas is bound by the irrelevant tetramer DR1-HA, which contains the
immunodominant determinant of hemagglutinin [8]). These data confirm that that our A12/DR1-tetramer recognizes only the collagen-specific,
DR1-restricted T cells in our panel.
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Figure 2 Ex vivo analysis of the development of the A12-specific T-cell response in DR1 Tg mice. DR1 mice were immunized with either
A12 or OVA, and individual mice were killed on day 10 after immunization. Cells from inguinal lymph nodes were collected and either analyzed
immediately (a, b) or stimulated for 4 days with the A12 peptide or Ova before analysis (c, d). (Lower panel) DR1 mice were immunized with
either CII/CFA (e) or Ova (f) and, at the time of onset of arthritis, were treated subcutaneously (100 μg/mouse in IFA) with either A12 peptide (e)
or Ova (right) (f). Cells were collected from inguinal lymph nodes on day 26 after treatment with peptide, and the cells were analyzed for the
presence of tetramer-positive cells directly ex vivo with flow cytometry. All cells were analyzed for the presence of A12-specific T cells by using
the DR1-A12 tetramer and anti-CD3 or anti-CD4, anti-CD8, and anti-CD19. Anti-CD8 and anti-CD19 were used simultaneously in the FL4 channel,
and anti-CD3 or anti-CD4 was used in the FL1 channel. The cells represented are CD19-/CD8-/CD3+ or CD19-/CD8-/CD4+. Data are representative
of at least six mice per time point and are based on a minimum of 100,000 cells analyzed.
Kimata et al. Arthritis Research & Therapy 2012, 14:R107
http://arthritis-research.com/content/14/3/R107
Page 6 of 13
Mechanism of suppression
A major mechanism by which T cells function is through
the secretion of cytokines, either inflammatory (Th1,
Th17) or suppressive (Th2). To test for cytokine secretion,
cells from the inguinal lymph nodes of mice previously
immunized with A12/CFA were fractionated with ferro-
magnetic beads into tetramer+ and tetramer- subsets and
cultured with APCs pulsed with the immunodominant
collagen peptide. Control T cells were purified from mice
immunized with either CII or Ova. As shown in Figure 4,
supernatants from tetramer+ cell cultures contained pre-
dominantly Th2/suppressive cytokines (IL-4 and IL-10) in
response to collagen, whereas the tetramer-negative popu-
lation did not react. Conversely, control A2-specific T
cells (from CII-immunized mice) secreted both suppres-
sive (IL-4 and IL-10) and inflammatory (IFN-g and IL-17)
cytokines to collagen, whereas Ova-responsive cells were
generally nonreactive. These data make it clear that tetra-
mer+ cells are responsible for the suppressive cytokine
secretion after activation by A12. Very little evidence sug-
gests that Tregs, NKT cells, or any other potential sup-
pressive subsets play a major role.
To date, our studies of A12-tetramer+ T cells have
focused primarily on T cells detected in inguinal lymph
nodes after immunization with A12/CFA. Interestingly,
when T cells from inguinal lymph nodes of cells immu-
nized with CII/CFA (without treatment with analog)
were collected 10 days after immunization and stained
for the presence of A12-tetramer+ T cells, we detected a
small population (0.86 ± 0.2 A12-tetramer+ T cells com-
pared with 0.23 ± 0.04 tetramer+ T cells from Ova immu-
nized mice (P ≤ 0.007 from three separate analyses).
Although more work must be done to characterize defi-
nitively the cytokine profiles and phenotypes of these
cells, we have found that T cells collected from lymph
nodes after immunization with CII/CFA secrete
Table 1 Analysis of TCR Vb use in A12-tetramer+ T cells




VB5 (5.1, 5.2). < 1
VB6 < 1
VB7 < 1






VB14 68.6 ± 10
VB17 < 1
To determine the frequency of individual Vb subfamilies expressed by
tetramer+ T cells in DR1 mice, draining inguinal cells from DR1 mice
immunized 10 days earlier with A12/CFA were incubated with tetramer
labeled with PE, anti-CD4-APC, anti-a/bTCR-PerCP, and an anti-TCR-Vb-specific
Ab conjugated with FITC. Labeled cells were analyzed from each sample with
flow cytometry, and the final analysis was performed by using FlowJo
software. Data shown represent the mean values from three separate
analyses. Virtually all the tetramer+ T cells expressed either the Vb14 or the
Vb8 (Vb8.1, Vb8.2, or Vb8.3) TCR segment, identifying them as the major T-cell


























Figure 3 A12-responsive T cells are not Tregs. Inguinal lymph node cells from DR1 Tg mice immunized 10 days earlier with A12/CFA (left
panel), A2/CFA (middle panel), or Ova/CFA (right panel) were cultured directly ex vivo with anti CD25, CD4+, VB8+, VB14+, and intracellular FoxP3.
Selective gating was performed on the CD4+, VB8+VB14+ cells. Before intracellular staining, a sample of the A12-specific cells was stained with
DR1-A12 tetramer to confirm that the VB8+, VB14+ population was enriched for tetramer+ cells (15% tetramer+). The experiments were repeated
after 4 days of culture with the A12 peptide in vitro, and the results were similar to those shown. These data indicate that the numbers of Foxp3
+, CD25+ Treg cells remain at background levels after immunization with A12/CFA.
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suppressive cytokines (primarily IL-4 and IL-10) in
response to A12/DR1 and not inflammatory cytokines
[6]. These data suggest that activated T cells can be redir-
ected to respond to the analog with a suppressive cyto-
kine profile and that this redirection can occur in a
setting of active inflammation. Moreover, we have found
that the cytokine response to the analog A12 remains
suppressive, regardless of which routes were used for
administration or whether the peptide was given before
or after immunization [6].
Role of IL-4 and IL-10 in A12 suppression
We previously showed that IL-4 can attenuate arthritis.
However, it remained unclear whether other cytokines
affect the A12 mechanism of action. To confirm and
compare the importance of other Th2 cytokines in vivo,
we developed DR1 mice that were genetically deficient in
IL-4 and IL-10, so that groups of 10 IL-4-/- or IL-10-/-
mice could be treated with A12 at the time of immuniza-
tion with CII/CFA and compared with wild-type DR1
mice for the severity of the development of arthritis. As
shown in Figure 5, the cytokine IL-10 appears to play a
partial role in the A12 prevention of arthritis (Figure 5),
whereas IL-4 is more potent. Interestingly, T cells from
A12-treated IL-10-/- mice produced IL-4 when cultured
with collagen (IL-4 = 76 ± 21 pg/ml), but the levels were
not different from those produced by A12-treated IL-10
+/+ T cells (IL-4 = 65 ± 14 pg/ml). These data extend our
previous observation to confirm that the effectiveness of
A12 in treating arthritis is mediated at least in part by
both IL-4 and IL-10.
Treatment of arthritis
To resolve whether tetramer-positive T cells could suc-
cessfully suppress arthritis in the CIA model, we per-
formed passive transfer experiments [18]. Draining
inguinal lymph node cells from DR1/TCR Tg mice









































































Figure 4 Cytokine responses to A12-tetramer+ cells. DR1 mice were immunized with Ova (open bars), CII (solid bars), or A12 (hashed and
striped bars), and the draining inguinal lymph node cells were selected to obtain the CD4+ populations. The A12-immunized lymph node cells
were further fractionated into tetramer+ (left hashed bars) and tetramer- (striped bars) populations. The cells were cultured (5 × 105 CD4+ T cells/
ml) with wild-type APC (DR1-positive splenocytes; 1:2 ratio) prepulsed in vitro with the immunodominant collagen peptide. Supernatants were
collected and tested for the presence of each cytokine by using a multiplexed ELISA. The supernatants were collected from Ova-specific CD4+ T
cells (open bars), CII-specific T cells (solid bars), DR1-A12 tetramer+ T cells (left hashed bars), or tetramer- T cells (striped bars). Results shown
represent the mean ± SD of three separate experiments and are expressed in picograms per milliliter of culture supernatants. The Th1/Th2 ratio
was 13:1 in T cells responding to CII, whereas the Th1/Th2 ration was 0.5:1 in the DR1-A12 tetramer+ T cells.
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Figure 5 Analog peptides in IL4-/- and IL10-/- mice. Groups of DR1+ IL-4-/- , DR1 IL4+/+ littermates, DR1 IL10-/-, and DR1 IL10+/+ littermate mice
were immunized with CII/CFA. Mice were treated with either the A12 peptide or Ova (0.6 mg) subcutaneously in IFA at the time of
immunization. The mean severity scores for arthritis are shown at various times after immunization. The DR1 IL4+/+ mice treated with A12 differ
significantly from DR1 IL4+/+ mice treated with Ova (P < 0.0005 on day 53). Conversely, the DR1 IL4-/- group treated with A12 did not differ from
Ova-treated controls. Data shown are representative of four separate experiments. Similarly, the DR1 IL10+/+ mice treated with A12 were
significantly suppressed when compared with the DR1 IL10+/+ mice treated with Ova, P < 0.001 on day 53). Although the DR1 IL10-/- mice had
suppression of arthritis compared with Ova-treated controls (P ≤ 0.05), the suppression was not as potent as that obtained with DR1 IL10+/+
mice. Similarly, the incidence of arthritis was 15% in IL10+/+ A12-treated mice, which was significantly different from that of OVA-treated IL10+/+
mice (67%; P = 0.004). Conversely, the A12-treated IL10-/- mice had an arthritis incidence of 36%, which was not statistically different from the
IL10+/+ Ova-treated mice. Data shown are representative of three separate experiments.
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previously immunized with A12/CFA were collected, and
tetramer+ cells were fractionated by using ferromagnetic
beads. Either tetramer+ cells or tetramer- controls were
infused intravenously into DR1 tg mice, by using a (pre-
vention protocol) so that mice could be observed for
effects on collagen-induced arthritis. When infused before
the induction of arthritis, we observed (Figure 6A), that
the tetramer+ population of A12-immune T cells was
extremely effective in suppressing arthritis, compared with
tetramer-negative control LN cells.
With a different strategy to enrich for A12-responsive
T cells, we collected Vb8 and Vb14 populations from
A12-immunized lymph nodes by means of ferromagnetic
beads and subset-specific antibodies for positive selec-
tion. Flow cytometry confirmed that this population was
highly enriched for the tetramer+ T cells before infusion
into mice. When these cells were given to mice after
arthritis had been established (Figure 6B), arthritis was
significantly attenuated. Mean antibody titers to CII
taken 6 weeks after immunization were decreased in
mice given the Vb8-, Vb14- enriched T cells, compared
with mice given Vb8, Vb14- CD4+ T cells (Table 2).
To confirm the effectiveness of tetramer+ T cells in vivo,
inguinal lymph node cells were taken from the mice 28
days after treatment and were cultured with collagen so
that supernatants could be analyzed. When cultures from
mice treated with the Vb8+, Vb14+ cells were tested for
cytokines, the IL-4 response to murine collagen was
increased, whereas the levels of the inflammatory cyto-
kines were decreased when compared with those from
mice treated with the Vb8-, Vb14- cells (Table 2). Collec-
tively, the in vivo and in vitro experiments confirm that
the suppression of arthritis by A12-specific T cells involves
active secretion of suppressive cytokines (specifically IL-4
and IL-10), resulting in a downregulation in the inflamma-
tory cytokines IL-17 and IFN-g.
Discussion
The development of class II MHC tetramers has been
more challenging than that of class I tetramers, in part
because, unlike class I (which can be assembled from HLA
heavy chain, and excess peptide and b2-microglobulin),
the class II molecule is an assembly of a and b chains,
both of which are required for peptide binding. Proper
folding is required for the formation of a stable complex.
The most successful strategy involves producing empty
class II molecules that can be loaded with exogenous pep-
tide and assembled as MHC tetramers. However, A12 has
an extremely low binding avidity for the MHC, making
that approach unlikely to be successful. In this study, we
developed a highly specific HLA-DR1-A12 tetramer in
which we overcame the low-avidity problem by covalently
linking the peptide to the DR1. This strategy allows
successful identification of A12-specific T cells in the
wild-type mouse.
Ex vivo studies revealed the expansion of A12-specific T
cells in the inguinal lymph nodes after treatment with the
peptide. Moreover, we showed that DR1-A12 tetramer+ T
cells have significant antigen-specific characteristics,
including a limited TCR repertoire, and the expression of
high levels of Th2/suppressive cytokines despite constitut-
ing only 1.5% or less of the CD4+ population in vivo. The
population of A12-specific T cells can be expanded in
vitro to increase fivefold after 4 days of culture. Although
the numbers of A12-specific T cells may be small in terms
of the total CD4+ T-cell population, this still represents at
least a 1,000-fold expansion of these cells, given an esti-
mated antigen-specific T-cell precursor frequency of 105
to 106. In all, this approach demonstrates that a detailed
ex vivo image of the developing T-cell response to an ana-
log peptide can be achieved by using class II tetramers,
and our data suggest that analog-specific T cells can
expand in vivo and remain detectable in draining lymph
nodes for a significant period.
The T cells identified by the A12-CII tetramer expressed
primarily Th2/suppressive cytokines (IL-4 and IL-10) that
are associated with autoimmune suppression. In compari-
son, control cells specific for collagen secreted significant
amounts of all subclasses of cytokines, both inflammatory
(IFN-g, IL-17) and noninflammatory (IL-4 and IL-10).
Both IL-10 and IL-4 are known to suppress CIA when
they are administered to mice [19-22]. By using mice
genetically deficient in either IL-4 or IL-10 that have been
treated with the A12 peptide, we now extend our previous
studies to demonstrate that both cytokines play an impor-
tant role in the function of A12, IL-4 > IL-10. Our pre-
vious work is consistent with the concept that Th2/
suppressive cytokines have a unique role in the suppres-
sion of arthritis [23]. These elevated levels of Th2 cyto-
kines in the tetramer+ T cells support their identification
as A12-specific T cells. They probably play a significant
role in promoting the development of suppression in this
arthritis model.
This tetramer-based approach to the analysis of an
autoimmune T-cell response offers several advantages
over conventional approaches. First, cells are studied ex
vivo, thus avoiding any tissue-culture effects on gene
expression and T-cell function. Stable tetramer binding
to T cells can be achieved within 2 hours, and the assay
is performed at physiologic temperatures. Second, all
measurements of phenotype and function are focused on
T cells of the specificity of interest instead of an averaged
analysis of the total T population derived from the lym-
phoid tissue. Although the frequency of the Ag-specific
CD4+ T cells of interest is low both in our analyses and
in those of others [24], this problem can be overcome by
Kimata et al. Arthritis Research & Therapy 2012, 14:R107
http://arthritis-research.com/content/14/3/R107
Page 10 of 13
















































Figure 6 Cell transfer: prevention of arthritis. Tetramer+ T cells from draining lymph nodes were collected from DR1Tg mice immunized 10 days
earlier with A12/CFA. DR1 mice (n = 3) were infused with 2 × 105 cells of either tetramer+ or tetramer-, A12-primed CD4+ T cells. All recipients were
immunized with CII/CFA on the day of the cell transfer and observed for arthritis. (A) Mean severity scores over time. As indicated, only the tetramer+
A12-immune cells could prevent collagen-induced arthritis (final severity scores comparing square versus triangle of 1.3 ± 2.5 versus 5.4 ± 3.2; P ≤ 0.01.
The cell-transfer experiments have been repeated with both unfractionated cells and VB8+, VB14+ purified T cells from A12-immunized lymph nodes
with similar results. Suppression of established arthritis (B). Inguinal lymph node cells from A12-immunized DR1 mice were fractionated into a VB8,
VB14+ population and a VB8, VB14- population. DR1 mice (n = 10) were immunized with CII/CFA and observed for the development of arthritis. On
day 23 after immunization, when arthritis was established, each mouse was infused intravenously with 5 × 105 cells of either VB8, VB14+ T cells
(enriched for 7.5 × 104 tetramer+ cells) or VB8, VB14- T cells. (B) Mean severity scores over time. As shown, only the VB8, VB14+ A12-immune T cells
could suppress active arthritis in the collagen-induced arthritis model (final severity scores comparing (triangle versus circle) of 1.5 ± 1.0 versus 5.6 ±
1.6; P ≤ 0.03). Data shown are representative of three separate experiments.
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analysis of large numbers of cells and by focusing the
analysis on specific subpopulations. In terms of data
acquisition and analysis, we found that care must be
taken in quantitating these low-frequency events, because
background or nonspecific fluorescence can significantly
compete with a 1% or less positive population. The use of
both inclusion (CD3+ or CD4+) and exclusion (CD8-/
CD19-) gates for data analysis helped to ensure the high
degree of sensitivity and reproducibility in identifying
these low-percentage events.
Although the A12-specific T-cell response could be
clearly visualized by our DR-A12 tetramers, some ques-
tions remain as to whether these tetramers detect all the
DR1-restricted CD4+ T cells specific for the A12 peptide.
Although the frequency of A12-specific T cells we
observed is similar to that reported in other MHC class II
tetramer-based studies of Ag-specific T cells, it is still pos-
sible that we are failing to identify some small population
of CII-specific T cells that might have low affinity for
DR1-A12 or for some other unknown reason fail to bind
the tetramer. Despite these concerns, however, this tetra-
mer-based approach has significantly broadened our
understanding of the role and function of analog-specific
T cells in wild-type mice. The detection of A12-specific T
cells in the inguinal lymph nodes of arthritic animals after
treatment with peptide and the discovery that tetramer+ T
cells can suppress arthritis when infused into arthritic
mice indicates that these cells may play a direct role in
altering the course of autoimmune disease.
Conclusions
The success of the altered peptide ligand, glatiramer
acetate (Copaxone), in treating patients with multiple
sclerosis (MS), suggests that peptide therapies based on
naturally occurring proteins may provide an effective
alternative for the treatment of autoimmune arthritis.
Copaxone is a mixture of peptides composed of four
randomly arranged amino acids (L-alanine, L-lysine, L-
glutamic acid, and L-tyrosine), whose chemical structure
resembles that of the myelin basic protein molecule
[25]. The mechanism of action of successful APLs
appears to be the induction of inhibitory T cells, so that
inactivated T cells become Th2/inhibitory cells (which
secrete antiinflammatory cytokines) instead of Th1 and
Th17 cells (which secrete proinflammatory cytokines), a
phenomenon known as “immune deviation.” The effec-
tiveness of A12 is based on its ability to transform both
potential inflammatory T cells and/or bystander T cells
into therapeutic (regulatory-like) T cells [3]. Moreover,
this deviation also downregulates other proinflammatory
Th1 and Th17 cells, regardless of their antigenic specifi-
city, in a process known as “bystander suppression.”
APLs are potentially safer than existing therapies
because they contain a modification of an endogenous
naturally occurring protein, used to arrest the autoim-
mune T-cell attack and allow tissue repair.
We demonstrated that peptide/MHC multimers can
be used to detect inhibitory cells induced by altered
peptide ligands, even when the peptides have extremely
low avidity for the MHC. These cells are highly effective
in suppressing autoimmune arthritis. These data demon-
strate that analog-specific multimers are powerful tools
for detecting inhibitory T cells, useful for studies of
human T cells in upcoming clinical trials for RA. We
anticipate that future studies will outline the differences
between A12-specific T cells from healthy control sub-
jects and patients with RA.
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